Welcome!

News Feed Item

North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

NEW YORK, Dec. 17, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
http://www.reportlinker.com/p0763031/North-America-In-Vitro-Diagnostics-Market-Outlook-to-2018--Clinical-Chemistry-Genetic-Testing-Haematology-Histology-and-Cytology-Immuno-Chemistry-Infectious-Immunology-and-Microbiology-Culture.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData's new report, "North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" provides key market data on the North America In Vitro Diagnostics market – Canada and United States. The report provides value (USD million) data for all the market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Countries covered include Canada and United States.
- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the market categories and countries.
- Global corporate-level profiles of key companies operating within the North America In Vitro Diagnostics market..
- Key players covered include Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., Alere Inc. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the North America In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 15
2 Introduction 16
2.1 What is This Report About? 16
3 In Vitro Diagnostics in North America 17
3.1 In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-2018 17
3.2 In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-2018 18
3.3 In Vitro Diagnostics, North America, Company share (2010-2011) 26
4 In Vitro Diagnostics In United States 28
4.1 In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 28
4.2 In Vitro Diagnostics, United States, Distribution Share (2010-2011) 34
4.3 In Vitro Diagnostics, United States, Company Share (2010-2011) 38
5 In Vitro Diagnostics In Canada 51
5.1 In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, 2004-2018 51
5.2 In Vitro Diagnostics, Canada, Distribution Share (2010-2011) 57
5.3 Clinical Chemistry Distribution Share (2010-2011) 57
5.4 In Vitro Diagnostics, Canada, Company Share (2010-2011) 61
5.5 Microbiology Culture, Canada, Company Share (2010-2011) 75
6 Overview of Key Companies in North America In Vitro Diagnostics 77
6.1 Siemens Healthcare 77
6.2 Abbott Laboratories 78
6.3 F. Hoffmann-La Roche Ltd. 79
6.4 Beckman Coulter, Inc. 80
6.5 Ortho-Clinical Diagnostics Inc. 81
6.6 Alere Inc. 82
6.7 bioMerieux S.A. 83
6.8 Becton, Dickinson and Company 83
6.9 Bio-Rad Laboratories, Inc. 84
6.10 Sysmex Corporation 84
6.11 Qiagen N.V. 85
6.12 Gen-Probe Incorporated 85
6.13 DiaSorin S.p.A 86
6.14 Immucor, Inc. 86
6.15 Thermo Fisher Scientific Inc. 87
6.16 Hologic, Inc. 87
6.17 Cepheid 88
6.18 PerkinElmer, Inc. 88
6.19 Grifols, S.A. 89
6.20 ELITech Group 89
6.21 Life Technologies Corporation 90
6.22 Horiba, Ltd. 90
6.23 Biomedica Diagnostics Inc. 91
6.24 Diagnostica Stago, Inc. 91
6.25 OraSure Technologies, Inc. 91
7 North America Market Pipeline Products 92
7.1 Clinical Chemisty Market Pipeline Products 92
7.2 Immuno Chemistry Market Pipeline Products 99
7.3 Haematology Market Pipeline Products 110
7.4 Infectious Immunology Market Pipeline Products 112
7.5 Microbiology Culture Market Pipeline Products 119
7.6 Histology And Cytology Market Pipeline Products 121
7.7 Genetic Testing Market Pipeline Products 122
8 Financial Deals Landscape 127
8.1 Acquisition 127
8.2 Partnerships 177
9 Recent Developments 442
9.1 Strategy And Business Planning 442
9.2 Research And Development 474
9.3 Legal and Regulatory 482
9.4 Government and Public Interest 511
9.5 Product News 572
10 Appendix 734
10.1 Definitions of Markets Covered in the Report 735
10.2 Research Methodology 746
10.3 Secondary Research 746
10.4 Primary Research 747
10.5 Models 747
10.6 Forecasts 748
10.7 Expert Panels 748
10.8 GlobalData Consulting 748
10.9 Currency Conversion 749
10.10 Contact Us 749
10.11 Disclaimer 749

List of Tables

Table 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m),USD Constant, 2004-2018 44
Table 2: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-2018 46
Table 3: In Vitro Diagnostics, North America, Cross-Category Analysis, 2004-2018 48
Table 4: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Historic, 2004-2011 50
Table 5: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 52
Table 6: In Vitro Diagnostics, North America, Company share by Revenue ($m), USD Constant, 2010-2011 54
Table 7: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 56
Table 8: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011 58
Table 9: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 60
Table 10: Clinical Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 61
Table 11: Genetic Testing, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 61
Table 12: Haematology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 62
Table 13: Histology And Cytology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 62
Table 14: Immuno Chemistry, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 63
Table 15: Infectious Immunology, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 63
Table 16: Microbiology Culture, United States, Distribution Share by Revenue ($m), USD Constant, 2010-2011 64
Table 17: In Vitro Diagnostics, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 66
Table 18: Clinical Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 67
Table 19: Genetic Testing, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 69
Table 20: Haematology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 71
Table 21: Immuno Chemistry, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 73
Table 22: Infectious Immunology, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 75
Table 23: Microbiology Culture, United States, Company Share by Revenue ($m), USD Constant, 2010-2011 77
Table 24: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, 2004-2018 79
Table 25: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Historic, 2004-2011 81
Table 26: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 83
Table 27: Clinical Chemistry, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 84
Table 28: Genetic Testing, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 84
Table 29: Haematology, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 85
Table 30: Histology And Cytology, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 85
Table 31: Immuno Chemistry, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 86
Table 32: Infectious Immunology, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 86
Table 33: Microbiology Culture, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011 87
Table 34: In Vitro Diagnostics, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 89
Table 35: Clinical Chemistry, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 91
Table 36: Genetic Testing, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 93
Table 37: Haematology, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 95
Table 38: Histology And Cytology, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 97
Table 39: Immuno Chemistry, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 99
Table 40: Infectious Immunology, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 101
Table 41: Microbiology Culture, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011 103
Table 42: Clinical Chemisty Market Pipeline Products 119
Table 43: Immuno Chemistry Market Pipeline Products 126
Table 44: Haematology Market Pipeline Products 137
Table 45: Infectious Immunology Market Pipeline Products 139
Table 46: Microbiology Culture Market Pipeline Products 146
Table 47: Histology And Cytology Market Pipeline Products 148
Table 48: Genetic Testing Market Pipeline Products 149
Table 49: SQI Diagnostics Plans For Sale Of The Company 154
Table 50: Sparton Completes Acquisition Of Onyx EMS, Contract Manufacturing Services Provider, For $43 Million 155
Table 51: ERBA Diagnostics Acquires Drew Scientific, Maker Of Analytical Instruments And Reagents, For $6.5 Million 157
Table 52: Measurement Specialties Acquires Cambridge Technologies And Resistance Temperature Detector Company For $18.8 Million 159
Table 53: Atossa Genetics Acquires Acueity Healthcare, Diagnostic Device Provider 160
Table 54: AccelPath Acquires DigiPath Solutions For $2.4 Million 161
Table 55: Danaher Completes Acquisition Of 91.6% Stake In Iris International, Diagnostic Test Maker, For $324 Million 162
Table 56: Charles River Labs Acquires Accugenix, Provider Of Microbe Identification Services, For $17 Million 164
Table 57: Leica Biosystems Completes Acquisition Of Aperio Technologies 166
Table 58: Metabolon Acquires Lipomics Technologies, Diagnostics Company 169
Table 59: Waters Acquires Blue Reference, Maker Of Application Scientific Databases, For $14 Million 171
Table 60: Life Technologies Acquires Pinpoint Genomics, Molecular Diagnostics Company 172
Table 61: Thermo Fisher Scientific Completes Acquisition Of One Lambda, Transplant Diagnostics Company, For $925 Million 173
Table 62: Life Technologies Acquires Navigenics 175
Table 63: Genova Diagnostics Acquires Metametrix, Clinical Laboratory 177
Table 64: 23andMe Acquires CureTogether, Healthcare IT Company 178
Table 65: Luminex To Acquire GenturaDx, Molecular Diagnostics Company, For $50 Million 179
Table 66: Systagenix Acquires O2 Insights 181
Table 67: Maxxam Analytics Acquires Becquerel Labs, Provider Of Testing Services 182
Table 68: LabCorp Completes Acquisition Of Medtox Scientific For $241 Million 183
Table 69: Flagship Biosciences Acquires Ihctech, Provider Of Research Immunohistochemistry And Histology Services 185
Table 70: Halo Healthcare Acquires NeoMatrix, Maker Of Diagnostic Equipments 186
Table 71: Pacepartners To Acquire Vivione BioSciences 187
Table 72: Qiagen Acquires AmniSure International, Manufacturer Of Non Invasive Test Solutions 188
Table 73: Hologic Completes Acquisition Of Gen-Probe For $3.7 Billion 189
Table 74: Haemonetics To Acquire Hemerus Medical, Provider Of Leukoreduction Technologies, For $27 Million 192
Table 75: IntegenX Acquires SV, Provider Of DNA Identification Consumable Products, From GE Healthcare Bio-Sciences 194
Table 76: Beckman Coulter Acquires Blue Ocean Biomedical From Npe Systems 195
Table 77: Abcam Completes Acquisition Of Epitomics, Rabbit Monoclonal Antibodies Provider, For $155 Million 196
Table 78: Ontario Genomics Institute Acquires Minority Stake In RNA Diagnostics For $0.1 Million 198
Table 79: PhotoVoltaic Solar Cells Acquires MetaStat, Life Science Company 199
Table 80: Alere To Acquire eScreen, Provider Of Health Testing Products And Services, For Up To $340 Million 200
Table 81: Bode Technology Group Acquires Provider Of DNA Analysis Testing Services, Chromosomal Labs 202
Table 82: Signal Genetics To Acquire Molecular Diagnostics Company, ChipDX 203
Table 83: Multiple Myeloma Research Foundation Enters Into Co-Development Agreement With GenoSpace 204
Table 84: Empire Genomics Enters Into Licensing Agreement With Emory University For Genomic Biomarkers 205
Table 85: NanoPass Technologies Enters Into Licensing Agreement With Janssen Pharma For MicronJet 206
Table 86: Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For Transcreener Epigen Methyltransferase Assay 207
Table 87: BioView Enters Into Agreement With Abbott To Develop Automated Cancer Screening System 209
Table 88: Institute of Microelectronics Enters Into Co-Development Agreement With SFC Fluidics 210
Table 89: HTG Molecular Diagnostics Enters Into Licensing Agreement With Centre of Excellence for Prevention of Organ Failure For COPD Prognostic Test 211
Table 90: Pressure BioSciences Enters Into Co-Marketing Agreement With Constant Systems For High Pressure Technologies 212
Table 91: CML HealthCare Enters Into Licensing Agreement With Mitomics For Prostate Cancer Test 214
Table 92: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 215
Table 93: DioGenix Enters Into Agreement With Fast Forward To Develop New Blood Test For Multiple Sclerosis 217
Table 94: GNS Healthcare Enters Into Agreement With Dana-Farber Cancer Institute and Mount Sinai School of Medicine 219
Table 95: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 221
Table 96: CombiMatrix Enters Into Co-Marketing Agreement With Pathology For Prenatal Tests 222
Table 97: Clinical Genomics Enters Into Licensing Agreement With Quest Diagnostics For Colon Cancer Markers 223
Table 98: Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 224
Table 99: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For Archimedes Particle Metrology System 226
Table 100: Malvern Instruments Enters Into Co-Marketing Agreement With Affinity Biosensors For Archimedes Particle Metrology System 227
Table 101: Exosome Diagnostics Enters Into Co-Development Agreement With Promega For Urine Clinical Sample Concentrator Kit 228
Table 102: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 229
Table 103: Ezose Enters Into Co-Development Agreement With Fast Forward For Multiple Sclerosis Biomarkers 230
Table 104: BioDot Enters Into Co-Marketing Agreement With JOT Automation 231
Table 105: Sequella Enters Into Licensing Agreement With LabCorp For B-Smart Technology 232
Table 106: LifeTech Scientific, DiNova Venture Partners, Themes Investment Partners And Broncus Technologies Partner To Form Broncus Medical 233
Table 107: Van Andel Institute Enters Into Co-Development Agreement With Emory University 235
Table 108: Merck Serono Enters Into Co-Development Agreement With Auxogyn For Early Embryo Viability Assessment Test 236
Table 109: PGXL Labs Enters Into Joint Venture Agreement With Essential Molecular Testing 237
Table 110: Broad Institute Enters Into Distribution Agreement With Appistry For Genome Analysis Toolkit 238
Table 111: Thermo Fisher Enters Into Co-Development Agreement With Immundiagnostik 239
Table 112: Sage Labs Enters Into Agreement With Ekam Imaging To Develop Imaging Assays 240
Table 113: Bruker Enters Into An Agreement With Nextval For High-throughput Screening Technology 241
Table 114: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 242
Table 115: RainDance Technologies Enters Into Co-Development Agreement With Integrated DNA Technologies For Digital PCR 243
Table 116: Amarantus BioSciences Enters Into Option For Licensing Agreement With Memory Dx For LymPro Blood Test 245
Table 117: Iverson Genetic Diagnostics Enters Into Licensing Agreement With Johns Hopkins University School For Molecular Diagnostic Tests 246
Table 118: Rosetta Genomics Amends Co-Marketing Agreement With Precision Therapeutics For miRview mets2 Assays 247
Table 119: Mitomics Enters Into Co-Marketing Agreement With LabCorp For Prostate Core Mitomic Test 248
Table 120: Trillium Diagnostics Enters Into Licensing Agreement With Leukocare For Sepsis Dx 250
Table 121: Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 251
Table 122: Vela Diagnostics Enters Into Licensing Agreement With Life Technologies 252
Table 123: Augurex Life Sciences Enters Into Licensing Agreement With Quest Diagnostics For 14-3-3n Biomarker 253
Table 124: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions 254
Table 125: Ingenuity Systems Enters Into Co-Development Agreement With Life Technologies For Diagnostic Solutions 256
Table 126: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test 258
Table 127: Genia Technologies Enters Into Co-Development Agreement With Columbia University And Harvard University 260
Table 128: NextBio Enters Into Agreement With Winship Cancer Institute of Emory University For Myeloma Biomarkers 262
Table 129: Proof Centre Enters Into Co-Development Agreement With AllerGen For Allergy Biomarkers 263
Table 130: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology 264
Table 131: Atossa Enters Into Co-Marketing Agreement With Diagnostics Test Group For MASCT System 265
Table 132: Genalyte Partners Scienion To Provide Sciflexarrayer Dispensers For Maverick Detection Platform 266
Table 133: CML HealthCare Enters Into Agreement With MaRS Innovation 267
Table 134: Life Technologies Enters Into Agreement With Bristol-Myers Squibb For Companion Diagnostics Development 268
Table 135: Agilent Technologies Enters Into Co-Marketing Agreement With Molecular Discovery 269
Table 136: Agilent Technologies Enters Into Co-Marketing Agreement With MRM Proteomics 270
Table 137: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test 271
Table 138: Illumina Enters Into Technology Integration Agreement With Partners HealthCare System 272
Table 139: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products 274
Table 140: ImaginAb Enters Into Co-Development Agreement With MacroGenics 275
Table 141: BellBrook Labs Enters Into Co-Development Agreement With Reaction Biology 276
Table 142: GVK Biosciences Enters Into Licensing Agreement With National Cancer Institute For GOBIOM Database 277
Table 143: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina 278
Table 144: Perkinelmer Enters Into Co-Development Agreement With Massachusetts General Hospital 279
Table 145: Affymetrix Enters Into Co-Development Agreement With Pathgen Dx 281
Table 146: Axela Enters Into Co-Marketing Agreement With OvaGene Oncology 282
Table 147: University of Michigan Enters Into Joint Venture Agreement With International Genomics Consortium 283
Table 148: Regulus Therapeutics Enters Into An Agreement With Biogen Idec For Biomarkers 284
Table 149: Curetis Enters Into Licensing Agreement With Cempra For Unyvero 285
Table 150: Foundation Medicine Enters Into Co-Development Agreement With Clovis Oncology 286

List of Figures

Figure 1: In Vitro Diagnostics, Cross Country Comparison, Revenue ($m), USD Constant, 2004-2018 44
Figure 2: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, 2004-2018 45
Figure 3: In Vitro Diagnostics, North America, Cross-Category Analysis, 2004-2018 47
Figure 4: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Historic, 2004-2011 49
Figure 5: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 51
Figure 6: In Vitro Diagnostics, North America, Company share (%), 2011 53
Figure 7: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, 2004-2018 55
Figure 8: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Historic, 2004-2011 57
Figure 9: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 59
Figure 10: In Vitro Diagnostics, United States, Company Share (%), 2011 65
Figure 11: Clinical Chemistry, United States, Company Share (%), 2011 67
Figure 12: Genetic Testing, United States, Company Share (%), 2011 68
Figure 13: Haematology, United States, Company Share (%), 2011 70
Figure 14: Immuno Chemistry, United States, Company Share (%), 2011 72
Figure 15: Infectious Immunology, United States, Company Share (%), 2011 74
Figure 16: Microbiology Culture, United States, Company Share (%), 2011 76
Figure 17: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, 2004-2018 78
Figure 18: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Historic, 2004-2011 80
Figure 19: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 82
Figure 20: In Vitro Diagnostics, Canada, Company Share (%), 2011 88
Figure 21: Clinical Chemistry, Canada, Company Share (%), 2011 90
Figure 22: Genetic Testing, Canada, Company Share (%), 2011 92
Figure 23: Haematology, Canada, Company Share (%), 2011 94
Figure 24: Histology And Cytology, Canada, Company Share (%), 2011 96
Figure 25: Immuno Chemistry, Canada, Company Share (%), 2011 98
Figure 26: Infectious Immunology, Canada, Company Share (%), 2011 100
Figure 27: Microbiology Culture, Canada, Company Share (%), 2011 102
Figure 28: Siemens Healthcare, Company Share (%), North America In Vitro Diagnostics Market, 2011 104
Figure 29: Abbott Laboratories, Company Share (%),North America In Vitro Diagnostics Market, 2011 105
Figure 30: F. Hoffmann-La Roche Ltd., Company Share (%),North America In Vitro Diagnostics Market, 2011 106
Figure 31: F. Hoffmann-La Roche Ltd., Company Share (%),North America In Vitro Diagnostics Market, 2011 107
Figure 32: Ortho-Clinical Diagnostics Inc., Company Share (%),North America In Vitro Diagnostics Market, 2011 108
Figure 33: Alere Inc, Company Share (%),North America In Vitro Diagnostics Market, 2011 109

Companies mentioned
Siemens Healthcare
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Beckman Coulter, Inc.
Ortho-Clinical Diagnostics Inc.
Alere Inc.
bioMerieux S.A.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Qiagen N.V.
Gen-Probe Incorporate


To order this report:
In_Vitro_Diagnostic Industry:
North America In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
"The Striim platform is a full end-to-end streaming integration and analytics platform that is middleware that covers a lot of different use cases," explained Steve Wilkes, Founder and CTO at Striim, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"With Digital Experience Monitoring what used to be a simple visit to a web page has exploded into app on phones, data from social media feeds, competitive benchmarking - these are all components that are only available because of some type of digital asset," explained Leo Vasiliou, Director of Web Performance Engineering at Catchpoint Systems, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
SYS-CON Events announced today that DXWorldExpo has been named “Global Sponsor” of SYS-CON's 21st International Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Digital Transformation is the key issue driving the global enterprise IT business. Digital Transformation is most prominent among Global 2000 enterprises and government institutions.
SYS-CON Events announced today that Datera, that offers a radically new data management architecture, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Datera is transforming the traditional datacenter model through modern cloud simplicity. The technology industry is at another major inflection point. The rise of mobile, the Internet of Things, data storage and Big...
Kubernetes is an open source system for automating deployment, scaling, and management of containerized applications. Kubernetes was originally built by Google, leveraging years of experience with managing container workloads, and is now a Cloud Native Compute Foundation (CNCF) project. Kubernetes has been widely adopted by the community, supported on all major public and private cloud providers, and is gaining rapid adoption in enterprises. However, Kubernetes may seem intimidating and complex ...
"Outscale was founded in 2010, is based in France, is a strategic partner to Dassault Systémes and has done quite a bit of work with divisions of Dassault," explained Jackie Funk, Digital Marketing exec at Outscale, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We focus on SAP workloads because they are among the most powerful but somewhat challenging workloads out there to take into public cloud," explained Swen Conrad, CEO of Ocean9, Inc., in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"I think DevOps is now a rambunctious teenager – it’s starting to get a mind of its own, wanting to get its own things but it still needs some adult supervision," explained Thomas Hooker, VP of marketing at CollabNet, in this SYS-CON.tv interview at DevOps Summit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We are still a relatively small software house and we are focusing on certain industries like FinTech, med tech, energy and utilities. We help our customers with their digital transformation," noted Piotr Stawinski, Founder and CEO of EARP Integration, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We've been engaging with a lot of customers including Panasonic, we've been involved with Cisco and now we're working with the U.S. government - the Department of Homeland Security," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...